Previous close | 42.75 |
Open | 42.54 |
Bid | 42.90 x 1000 |
Ask | 42.90 x 800 |
Day's range | 42.43 - 42.91 |
52-week range | 34.74 - 47.70 |
Volume | |
Avg. volume | 1,262,952 |
Market cap | 9.497B |
Beta (5Y monthly) | 0.41 |
PE ratio (TTM) | 28.04 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.28 (2.94%) |
Ex-dividend date | 30 Jan 2024 |
1y target est | N/A |
With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.
QIAGEN's (QGEN) collaboration with IPPA follows the updated CDC guidelines for TB screening for immigrants in the United States.
Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.